drugset / Trial / NCT03495167
Study of SyB C-1101 in Patients With Myelodysplastic Syndrome
NaSingle-groupOpen-labelTreatment
Summary
To assess tolerability of SyB C-1101 when administered orally BID for 21 days followed by a 7-day observation period in patients with recurrent/relapsed or refractory myelodysplastic syndrome in order to determine a recommended dose (RD). To assess safety, efficacy and pharmacokinetics.
Timeline
- Start
- 2017-10-06
- Primary completion
- 2019-05-28
- Completion
- 2019-05-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | rigosertib | Small molecule | 280 mg | Oral |
| Subject | rigosertib | Small molecule | 560 mg | Oral |
| Subject | rigosertib | Small molecule | 840 mg | Oral |